Alfimeprase: a novel recombinant direct-acting fibrinolytic

Bibliography

• RETZIOS AD, MARKLAND FS: A direct-acting fibrinolytic enzyme from the venom of Agkistrodon contortrix contortrix: effects on various components of the human blood coaguolation and fibrinolytic systems. Thromb. Res. (1988) 52:541-552.
   PubMed Web of Science ®Google Scholar
• SWENSEN S, MARKLAND FS, TOOMBS C: Fibrolase. In: Handbook of Proteolytic Enzymes (2nd Edition). Barrett AJ (Ed.), Elsevier Academic Press, London, UK (2004).
   Google Scholar
• MANNING MC: Sequence analysis of fibrolase, a fibrinolytic metalloproteinase from Agkistrodon contortrix contortrix. Toxicon (1995) 33:1189-1200.
   PubMed Web of Science ®Google Scholar
• RANDOLPH A, CHAMBERLAIN SH, CHU HL, RETZIOS AD, MARKLAND FS JR, MASIARZ FR: Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from Agkistrodon contortrix contortrix venom. Protein Sci. (1992) 1:590-600.
   PubMed Web of Science ®Google Scholar
• RETZIOS AD, MARKLAND FS: Fibrinolytic enzymes from the venoms of Agkistrodon contortrix contortrix and Crotalus basiliscus basiliscus: cleavage site specificity towards the alpha-chain of fibrin. Thromb. Res. (1994) 74:355-367.
   PubMed Web of Science ®Google Scholar
• PRETZER D, SCHULTEIS BS, SMITH CD, VANDER VD, MITCHELL JW, MANNING MC: Stability of the thrombolytic protein fibrolase: effect of temperature and pH on activity and conformation. Pharm.Res. (1991) 8:1103-1112.
   PubMed Web of Science ®Google Scholar
• BARRETT AJ: Alpha-2 macroglobulin. In: Methods in Enzymology. Barrett AJ (Ed.), Academic Press, Inc., New York, NY, USA (1981).
   Google Scholar
• PIZZO SV, WU SM: α-Macroglobulins and kunins. In: Hemostasis and Thrombosis. Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ (Eds), Lippincott, Williams and Wilkins, Philadelphia, PA, USA (2001).
   Google Scholar
• BERGQVIST D, NILSSON IM: Hereditary α2-macroglobulin deficiency. Scand.J.Haematol. (1979) 23:433-436.
   PubMedGoogle Scholar
• STENBJERG S: Inherited alpha2 macroglobulin deficiency. Thromb. Res. (1981) 22:491-495
   PubMed Web of Science ®Google Scholar
• POLLER W, BARTH J, VOSS B: Detection of an alteration of the α2-macroglobulin gene in a patient with chronic lung disease and serum α2-macroglobulin deficiency. Hum. Genet. (1989) 83:93-96.
   PubMed Web of Science ®Google Scholar
• KAHLES T, FOERCH C, SITZER M et al.: Tissue plasminogen activator mediated blood-brain barrier damage in transient focal cerebral ischemia in rats: Relevance of interactions between thrombotic material and thrombolytic agent. Vascul. Pharmacol. (2005) 43:254-259.
   PubMed Web of Science ®Google Scholar
• HURSTMANN S, KULB P, KOZIOL J, GARDNER H, WAGNER S: Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke (2003) 34:2171-2172.
   PubMed Web of Science ®Google Scholar
• WANG X, TSUJI K, LEE SR et al.: Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke (2004) 35:2726-2730.
   PubMed Web of Science ®Google Scholar
• NING M, FURIE KL, KOROSHETZ WJ et al.: Association between tPA therapy and raised early matrix metalloproteinase-9 in acute stroke. Neurology (2006) 66:1550-1555.
   PubMed Web of Science ®Google Scholar
• WANG X, LEE SR, ARAI K et al.: Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. (2003) 9:1313-1317.
   PubMed Web of Science ®Google Scholar
• HONG T-T, HUANG J, LUCCHESI BR: Effect of thrombolysis on myocardial injury: recombinant tissue plasminogen activator versus alfimeprase. Am. J. Physiol. Heart Circ. Physiol. (2005) 290(3):H959-H967.
   PubMed Web of Science ®Google Scholar
• TOOMBS CF: Alfimeprase. In: New Therapeutic Agents in Thrombosis and Thrombolysis (2nd Edition). Sasahara AA, Loscalzo J (Eds), Marcel Dekker, NY, USA (2003).
   Google Scholar
• DEITCHER SR, JAFF MR: Pharmacologic and clinical characteristics of thrombolytic agents. Rev. Cardiovasc. Med. (2003) 3(Suppl. 2):S25-S33.
   Google Scholar
• OURIEL K, SHORTELL CK, DEWEESE JA et al.: A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J. Vasc. Surg. (1994) 19:1021-1030.
   PubMed Web of Science ®Google Scholar
• BLAISDELL FW, STEELE M, ALLEN RE: Management of acute lower extremity arterial ischemia due to embolism and thrombosis. Surgery (1978) 84:822-834.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE Trial. Ann. Surg. (1994) 220:251-268.
   PubMed Web of Science ®Google Scholar
• OURIEL K, VEITH FJ, SASAHARA AA: A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators. N. Engl. J. Med. (1998) 338:1105-1111.
   PubMed Web of Science ®Google Scholar
• DEITCHER SR, FESEN MR, KIPROFF PM et al.: The safety and efficacy of alteplase (t-PA) for restoring function in occluded central venous catheters: Results of the Cardiovascular thrombolytic to Open Occluded Lines trial. J. Clin. Oncol. (2002) 20:317-324.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. (1995) 333:1581-1587.
   PubMed Web of Science ®Google Scholar
• MEWISSEN MW, SEABROOK GR, MEISSNER MH, CYNAMON J, LABROPOULOS N, HAUGHTON SH: Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology (1999) 211:39-49.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomized trial. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Lancet (2006) 367:569-578.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: Results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial. The ADVANCE MI Investigators. Am. Heart J. (2005) 150:116-122.
   PubMed Web of Science ®Google Scholar
• OURIEL K, CYNAMON J, WEAVER FA et al.: A Phase I trial of alfimeprase for peripheral arterial thrombolysis. J. Vasc. Interv. Radiol. (2005) 16:1075-1083.
   PubMed Web of Science ®Google Scholar
• MOLL S, KENYON P, BERTOLI L, DE MAIO J, HOMESLY H, DEITCHER SR: Phase II trial of alfimeprase, a novel acting fibrin degradation agent, for occluded central venous access devices. J. Clin. Oncol. (2006) 24:3056-3060.
   PubMed Web of Science ®Google Scholar
• SUMII T, LO EH: Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke (2002) 33:831-836.
   PubMed Web of Science ®Google Scholar
• HAHN-DANTONA EA, AIMES RT, QUIGLEY JP: The isolation, characterization, and molecular cloning of a 75-kDa gelatinase B-like enzyme, a member of the matrix metalloproteinase (MMP) family. An avian enzyme that is MMP-9-like in its cell expression pattern but diverges from mammalian gelatinase B in sequence and biochemical peoperties. J. Biol. Chem. (2000) 275:40827-40838.
   PubMed Web of Science ®Google Scholar